Norton Healthcare acquires groundbreaking focused ultrasound technology
14 oct. 2024 13h26 HE
|
Norton Healthcare
LOUISVILLE, Ky., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Norton Neuroscience Institute is the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
13 août 2024 07h00 HE
|
Praxis Precision Medicines, Inc.
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
05 mars 2024 07h00 HE
|
Praxis Precision Medicines, Inc.
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
08 janv. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
05 janv. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07 nov. 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
02 oct. 2023 13h17 HE
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
28 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
09 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA PRAX-628 Phase 1 study showed consistent safety profile and target engagement in...
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
08 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111) Patients...